Abstract
Glatiramer acetate (GA) significantly ameliorates multiple sclerosis and was initially discovered through its effects on the animal model experimental autoimmune encephalomyelitis (EAE). Guillain-Barré syndrome (GBS) is a relatively common demyelinating disease of peripheral nerves for which there is a parallel animal model, experimental autoimmune neuritis (EAN). We review the treatments found useful in EAN with special emphasis on the need for quick onset of action and the relevance of treatments used for EAE and multiple sclerosis. We evaluated the effect of GA administered by a novel intraperitoneal route in EAN. GA significantly ameliorated the severity of disease in rats (F = 6.3, p = 0.01 by analysis of variance (ANOVA)) and course of disease (F = 4.9, p = 0.02 by repeated-measures ANOVA with a day × treatment interaction term). Neurophysiology data supported the trend for the beneficial effect of GA. Myelin-induced immune cell proliferation was significantly modulated by GA (p < 0.025). This report describes a novel route of administration of GA and a rapid beneficial effect of GA in EAN. GA may be useful in human diseases, such as GBS, where the intravenous route may offer a rapid onset of drug action.
Similar content being viewed by others
References
Arnon R, Teitelbaum D, Sela M (1989) Suppression of experimental allergic encephalomyelitis by COP1—relevance to multiple sclerosis. Isr J Med Sci 25:686–689
Teitelbaum D, Arnon R, Sela M (1997) Copolymer 1: from basic research to clinical application. Cell Mol Life Sci 53:24–28
Soffer D, Feldman S, Alter M (1978) Epidemiology of Guillain-Barre syndrome. Neurology 28:686–690
Shoenfeld Y, George J, Peter JB (1996) Guillain-Barre as an autoimmune disease. Int Arch Allergy Immunol 109:318–326
Israeli E, Agmon-Levin N, Blank M, Chapman J, Shoenfeld Y (2010) Guillain-Barre Syndrome-A Classical Autoimmune Disease Triggered by Infection or Vaccination. Clin Rev Allergy Immunol doi:10.1007/s12016-010-8213-3
Kadlubowski M, Hughes RA (1979) Identification of the neuritogen for experimental allergic neuritis. Nature 277:140–141
Shin HC, McFarlane EF, Pollard JD, Watson EG (1989) Induction of experimental allergic neuritis with synthetic peptides from myelin P2 protein. Neurosci Lett 102:309–312
Waksman BH, Adams RD (1955) Allergic neuritis: an experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvants. J Exp Med 102:213–236
Mendell JR, Kissel JT, Kennedy MS, Sahenk Z, Grinvalsky HT, Pittman GL, Kyler RS, Roelofs RI, Whitaker JN, Bertorini TE (1985) Plasma exchange and prednisone in Guillain-Barre syndrome: a controlled randomized trial. Neurology 35:1551–1555
McDaneld LM, Fields JD, Bourdette DN, Bhardwaj A (2010) Immunomodulatory therapies in neurologic critical care. Neurocrit Care 12:132–143
Pithadia AB, Kakadia N (2010) Guillain-Barre syndrome (GBS). Pharmacol Rep 62:220–232
Vucic S, Kiernan MC, Cornblath DR (2009) Guillain-Barre syndrome: an update. J Clin Neurosci 16:733–741
Harel M, Shoenfeld Y (2005) Intravenous immunoglobulin and Guillain-Barre syndrome. Clin Rev Allergy Immunol 29:281–287
Kafri M, Kloog Y, Korczyn AD, Ferdman-Aronovich R, Drory V, Katzav A, Wirguin I, Chapman J (2005) Inhibition of Ras attenuates the course of experimental autoimmune neuritis. J Neuroimmunol 168:46–55
Kafri M, Drory VE, Wang N, Rabinowitz R, Korczyn AD, Chapman J (2002) Assessment of experimental autoimmune neuritis in the rat by electrophysiology of the tail nerve. Muscle Nerve 25:51–57
Maurer M, Toyka KV, Gold R (2002) Cellular immunity in inflammatory autoimmune neuropathies. Rev Neurol Paris 158:S7–S15
Zhang ZY, Zhang Z, Schluesener HJ (2010) MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis. Neuroscience 169:370–377
Zhang Z, Zhang ZY, Schluesener HJ (2009) Compound A, a plant origin ligand of glucocorticoid receptors, increases regulatory T cells and M2 macrophages to attenuate experimental autoimmune neuritis with reduced side effects. J Immunol 183:3081–3091
Tan XD, Dou YC, Shi CW, Duan RS, Sun RP (2009) Administration of dehydroepiandrosterone ameliorates experimental autoimmune neuritis in Lewis rats. J Neuroimmunol 207:39–44
Zhang Z, Zhang ZY, Fauser U, Schluesener HJ (2008) Valproic acid attenuates inflammation in experimental autoimmune neuritis. Cell Mol Life Sci 65:4055–4065
Zhang ZY, Zhang Z, Fauser U, Schluesener HJ (2009) Improved outcome of EAN, an animal model of GBS, through amelioration of peripheral and central inflammation by minocycline. J Cell Mol Med 13:341–351
Sarkey JP, Richards MP, Stubbs EB Jr (2007) Lovastatin attenuates nerve injury in an animal model of Guillain-Barre syndrome. J Neurochem 100:1265–1277
Bao L, Lindgren JU, Zhu Y, Ljunggren HG, Zhu J (2003) Exogenous soluble tumor necrosis factor receptor type I ameliorates murine experimental autoimmune neuritis. Neurobiol Dis 12:73–81
Taylor JM, Pollard JD (2007) Soluble TNFR1 inhibits the development of experimental autoimmune neuritis by modulating blood-nerve-barrier permeability and inflammation. J Neuroimmunol 183:118–124
Castro FR, Farias AS, Proenca PL, de La Hoz C, Langone F, Oliveira EC, Toyama MH, Marangoni S, Santos LM (2007) The effect of treatment with crotapotin on the evolution of experimental autoimmune neuritis induced in Lewis rats. Toxicon 49:299–305
Nicoletti F, Creange A, Orlikowski D, Bolgert F, Mangano K, Metz C, Di Marco R, Al Abed Y (2005) Macrophage migration inhibitory factor (MIF) seems crucially involved in Guillain-Barre syndrome and experimental allergic neuritis. J Neuroimmunol 168:168–174
Schmidt J, Elflein K, Stienekemeier M, Rodriguez-Palmero M, Schneider C, Toyka KV, Gold R, Hunig T (2003) Treatment and prevention of experimental autoimmune neuritis with superagonistic CD28-specific monoclonal antibodies. J Neuroimmunol 140:143–152
Miyamoto K, Oka N, Kawasaki T, Miyake S, Yamamura T, Akiguchi I (2002) New cyclooxygenase-2 inhibitors for treatment of experimental autoimmune neuritis. Muscle Nerve 25:280–282
Di Marco R, Khademi M, Wallstrom E, Muhallab S, Nicoletti F, Olsson T (1999) Amelioration of experimental allergic neuritis by sodium fusidate (fusidin): suppression of IFN-gamma and TNF-alpha and enhancement of IL-10. J Autoimmun 13:187–195
Hartung HP, Schafer B, Fierz W, Heininger K, Toyka KV (1987) Ciclosporin A prevents P2 T cell line-mediated experimental autoimmune neuritis (AT-EAN) in rat. Neurosci Lett 83:195–200
Bai XF, Zhu J, Zhang GX, Kaponides G, Hojeberg B, van der Meide PH, Link H (1997) IL-10 suppresses experimental autoimmune neuritis and down-regulates TH1-type immune responses. Clin Immunol Immunopathol 83:117–126
Jung S, Toyka K, Hartung HP (1996) T cell directed immunotherapy of inflammatory demyelination in the peripheral nervous system. Potent suppression of the effector phase of experimental autoimmune neuritis by anti-CD2 antibodies. Brain 119(Pt 4):1079–1090
Archelos JJ, Maurer M, Jung S, Toyka KV, Hartung HP (1993) Suppression of experimental allergic neuritis by an antibody to the intracellular adhesion molecule ICAM-1. Brain 116(Pt 5):1043–1058
Usuki S, Taguchi K, Thompson SA, Chapman PB, Yu RK (2010) Novel anti-idiotype antibody therapy for lipooligosaccharide-induced experimental autoimmune neuritis: use relevant to Guillain-Barre syndrome. J Neurosci Res 88:1651–1663
Jung S, Gaupp S, Korn T, Kollner G, Hartung HP, Toyka KV (2004) Biphasic form of experimental autoimmune neuritis in dark Agouti rats and its oral therapy by antigen-specific tolerization. J Neurosci Res 75:524–535
Zou LP, Ma DH, Levi M, Wahren B, Wei L, Mix E, van der Meide PH, Link H, Zhu J (1999) Antigen-specific immunosuppression: nasal tolerance to P0 protein peptides for the prevention and treatment of experimental autoimmune neuritis in Lewis rats. J Neuroimmunol 94:109–121
Offenhausser M, Herr AS, Hartkamp J, Wauben M, Magnus T, Grauer O, Seubert S, Weishaupt A, Toyka KV, Gold R, Troppmair J (2002) Truncation of the neuritogenic peptide bP2(60-70) results in the generation of altered peptide ligands with the potential to interfere with T cell activation. J Neuroimmunol 129:97–105
Dati G, Quattrini A, Bernasconi L, Malaguti MC, Antonsson B, Nicoletti F, Alliod C, Di Marco R, Sagot Y, Vitte PA, Hiver A, Greco B, Roach A, Zaratin PF (2007) Beneficial effects of r-h-CLU on disease severity in different animal models of peripheral neuropathies. J Neuroimmunol 190:8–17
Bechtold DA, Yue X, Evans RM, Davies M, Gregson NA, Smith KJ (2005) Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide. Brain 128:18–28
The Guillain-Barre syndrome Study Group (1985) Plasmapheresis and acute Guillain-Barre syndrome. Neurology 35:1096–1104
Enders U, Toyka KV, Hartung HP, Gold R (1997) Failure of intravenous immunoglobulin (IVIg) therapy in experimental autoimmune neuritis (EAN) of the Lewis rat. J Neuroimmunol 76:112–116
Gabriel CM, Gregson NA, Redford EJ, Davies M, Smith KJ, Hughes RA (1997) Human immunoglobulin ameliorates rat experimental autoimmune neuritis. Brain 120(Pt 9):1533–1540
Jia J, Jia J, Pollock M (2000) Treatment of rats with experimental allergic neuritis using high dose immunoglobulin. Chin Med J (Engl) 113:1096–1099
Lin HH, Spies JM, Lu JL, Pollard JD (2007) Effective treatment of experimental autoimmune neuritis with human immunoglobulin. J Neurol Sci 256:61–67
Lin HH, Wang MX, Spies JM, Pollard JD (2007) Effective treatment of experimental autoimmune neuritis with Fc fragment of human immunoglobulin. J Neuroimmunol 186:133–140
Miyagi F, Horiuchi H, Nagata I, Kitahara S, Kiyoki M, Komoriya K, Yuki N (1997) Fc portion of intravenous immunoglobulin suppresses the induction of experimental allergic neuritis. J Neuroimmunol 78:127–131
Hughes RA, Kadlubowski M, Hufschmidt A (1981) Treatment of acute inflammatory polyneuropathy. Ann Neurol 9(Suppl):125–133
Zhu J, Bai XF, Hedlund G, Bjork J, Bakhiet M, Van Der Meide PH, Link H (1999) Linomide suppresses experimental autoimmune neuritis in Lewis rats by inhibiting myelin antigen-reactive T and B cell responses. Clin Exp Immunol 115:56–63
Zou LP, Abbas N, Volkmann I, Nennesmo I, Levi M, Wahren B, Winblad B, Hedlund G, Zhu J (2002) Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology 42:731–739
Zou LP, Ma DH, Wei L, van der Meide PH, Mix E, Zhu J (1999) IFN-beta suppresses experimental autoimmune neuritis in Lewis rats by inhibiting the migration of inflammatory cells into peripheral nervous tissue. J Neurosci Res 56:123–130
Yu S, Chen Z, Mix E, Zhu SW, Winblad B, Ljunggren HG, Zhu J (2002) Neutralizing antibodies to IL-18 ameliorate experimental autoimmune neuritis by counter-regulation of autoreactive Th1 responses to peripheral myelin antigen. J Neuropathol Exp Neurol 61:614–622
Zhang Z, Zhang ZY, Fauser U, Schluesener HJ (2008) FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves. Exp Neurol 210:681–690
Zhang ZY, Zhang Z, Zug C, Nuesslein-Hildesheim B, Leppert D, Schluesener HJ (2009) AUY954, a selective S1P(1) modulator, prevents experimental autoimmune neuritis. J Neuroimmunol 216:59–65
O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T (2009) 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing–remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 8:889–897
McDermott JR, Keith AB (1980) Antigen-induced suppression of experimental allergic neuritis in the guinea pig. J Neurol Sci 46:137–143
Kadlubowski M, Hughes RA, Gregson NA (1980) Experimental allergic neuritis in the Lewis rat: characterization of the activity of peripheral myelin and its major basic protein, P2. Brain Res 184:439–454
Hoffman PM, Powers JM, Weise MJ, Brostoff SW (1980) Experimental allergic neuritis. I. Rat strain differences in the response to bovine myelin antigens. Brain Res 195:355–362
Aharoni R, Eilam R, Stock A, Vainshtein A, Shezen E, Gal H, Friedman N, Arnon R (2010) Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing–remitting or chronic EAE. J Neuroimmunol 225:100–111
Aharoni R, Teitelbaum D, Sela M, Arnon R (1997) Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 94:10821–10826
Begum-Haque S, Sharma A, Kasper IR, Foureau DM, Mielcarz DW, Haque A, Kasper LH (2008) Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis. J Neuroimmunol 204:58–65
Laura M, Gregson NA, Curmi Y, Hughes RA (2002) Efficacy of leukemia inhibitory factor in experimental autoimmune neuritis. J Neuroimmunol 133:56–59
Yu S, Zhu Y, Chen Z, Alheim M, Ljungberg A, Zhu J (2002) Initiation and development of experimental autoimmune neuritis in Lewis rats is independent of the cytotoxic capacity of NKR-P1A + cells. J Neurosci Res 67:823–828
Stienekemeier M, Falk K, Rotzschke O, Weishaupt A, Schneider C, Toyka KV, Gold R, Strominger JL (2001) Vaccination, prevention, and treatment of experimental autoimmune neuritis (EAN) by an oligomerized T cell epitope. Proc Natl Acad Sci USA 98:13872–13877
Felts PA, Smith KJ, Gregson NA, Hughes RA (2002) Brain-derived neurotrophic factor in experimental autoimmune neuritis. J Neuroimmunol 124:62–69
Acknowledgments
The study was supported by a grant from Teva Pharmaceuticals. We thank Dr. Liat Hayardeni for her very helpful critical discussion and review of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
Ramona Aronovich and Aviva Katzav contributed equally to this study.
Rights and permissions
About this article
Cite this article
Aronovich, R., Katzav, A. & Chapman, J. The Strategies Used for Treatment of Experimental Autoimmune Neuritis (EAN): A Beneficial Effect of Glatiramer Acetate Administered Intraperitoneally. Clinic Rev Allerg Immunol 42, 181–188 (2012). https://doi.org/10.1007/s12016-010-8246-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-010-8246-7